EffRx Pharmaceuticals, Radius Health Inks Agreement To Commercialize BINOSTO

EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of medications for musculoskeletal and rare diseases, announced that it has signed an exclusive licensing and distribution agreement for Binosto in the United States with Radius Health, Inc. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

BINOSTO provides an important once-weekly treatment option, particularly for patients with osteoporosis who may not be able to take alendronate tablets. Radius is a major player in the U.S. bone market and currently markets TYMLOS® for the treatment of osteoporosis in the U.S. BINOSTO expands Radius’ presence in the treatment of bone health with a second product for the approximately 10 million people in the U.S. living with osteoporosis, as per business wire. Scott Briggs, Chief Executive Officer of Radius, commented, "We are pleased to offer another product to support the needs of patients who are living with osteoporosis .

We have seen strong growth of TYMLOS® in the last year, and while it will remain a primary focus, BINOSTO® addresses an important unmet need particularly for patients who have difficulty swallowing pills." Ed Cinca, Chief Commercial Officer of Radius added, "The addition of BINOSTO® along with our currently marketed product TYMLOS® will allow Radius to expand its product offerings to healthcare providers treating osteoporosis. Given our success with TYMLOS®, we believe that we are well-positioned to support the future growth of BINOSTO®, which has been particularly successful in markets outside the U.S. We look forward to the introduction of BINOSTO in the coming months."